Latest Insider Transactions at Arbutus Biopharma Corp (ABUS)
This section provides a real-time view of insider transactions for Arbutus Biopharma Corp (ABUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arbutus Biopharma Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arbutus Biopharma Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 14
2024
|
Keith S Manchester Director |
SELL
Open market or private sale
|
Direct |
8,846
-16.11%
|
$26,538
$3.69 P/Share
|
|
Aug 14
2024
|
Keith S Manchester Director |
BUY
Exercise of conversion of derivative security
|
Direct |
54,915
+50.0%
|
$0
$0.56 P/Share
|
|
Feb 02
2024
|
David C Hastings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,593
-5.01%
|
$19,186
$2.31 P/Share
|
|
Feb 02
2024
|
Karen Sims Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,358
-3.35%
|
$8,716
$2.31 P/Share
|
|
Feb 02
2024
|
Michael J. Mc Elhaugh Interim President & CEO |
SELL
Open market or private sale
|
Direct |
10,164
-0.67%
|
$20,328
$2.31 P/Share
|
|
Feb 02
2024
|
Michael J. Sofia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,982
-0.67%
|
$19,964
$2.31 P/Share
|
|
Feb 01
2024
|
David C Hastings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+37.01%
|
-
|
|
Feb 01
2024
|
Karen Sims Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,000
+43.74%
|
-
|
|
Feb 01
2024
|
J. Christopher Naftzger General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
95,100
+50.0%
|
-
|
|
Feb 01
2024
|
Michael J. Mc Elhaugh Interim President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
123,800
+7.55%
|
-
|
|
Feb 01
2024
|
Michael J. Sofia Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,500
+6.82%
|
-
|
|
Feb 01
2023
|
Elizabeth Howard EVP, GC, Compliance |
BUY
Grant, award, or other acquisition
|
Direct |
69,700
+44.76%
|
-
|
|
Feb 01
2023
|
William H. Collier President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
216,500
+50.0%
|
-
|
|
Feb 01
2023
|
David C Hastings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
79,000
+50.0%
|
-
|
|
Feb 01
2023
|
Michael J. Sofia Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,200
+5.6%
|
-
|
|
Feb 01
2023
|
Michael J. Mc Elhaugh Interim President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
83,700
+5.68%
|
-
|
|
Dec 01
2021
|
Michael J. Sofia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
200,000
-13.3%
|
$1,000,000
$5.09 P/Share
|
|
Oct 18
2021
|
Roivant Sciences Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
22,833,922
+37.02%
|
-
|
|
Feb 09
2021
|
Michael J. Mc Elhaugh Interim President & CEO |
SELL
Open market or private sale
|
Direct |
20,000
-1.51%
|
$100,000
$5.0 P/Share
|
|
Dec 14
2020
|
Michael J. Mc Elhaugh Interim President & CEO |
SELL
Open market or private sale
|
Direct |
40,000
-1.47%
|
$200,000
$5.0 P/Share
|